Navigation Links
deCODE Reinstated to Nasdaq Global Market
Date:6/26/2009

REYKJAVIK, Iceland, June 26 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that it has received notice from the the Nasdaq Hearing and Listing Review Council that the listing of the company's common stock will be reinstated to the Nasdaq Global Market effective from the opening of trading on Monday, June 29. deCODE's common stock will continue to trade under the symbol DCGN.

The reinstatement follows the Listing Council's reversal of a decision in February by the Nasdaq Listing Qualifications Panel under which the listing of deCODE's common stock was transferred to the Nasdaq Capital Market.

About deCODE

deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com; on our diagnostics site at http://www.decodediagnostics.com; for our pioneering personal genome analysis service and new focused disease scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, as well as for our new deCODEme Cardio(TM) and deCODEme Cancer(TM) scans, at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contacts:
    deCODE genetics
    Edward Farmer
    +44-7796-010107
    edward.farmer@decode.is

    Gisli Arnason
    +354-570-1900
    gisli.arnason@decode.is

    Joy Bessenger
    +1-212-481-3891
    joy.bessenger@decode.is


'/>"/>
SOURCE deCODE genetics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
2. deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
3. deCODE genetics Announces First Quarter 2009 Financial Results
4. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
5. Nasdaq Stays Suspension of Trading in deCODE Stock
6. deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
7. deCODE to Utilize Grace Period for Interest Payment on Senior Convertible Notes
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
9. Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
10. deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market
11. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... 2017 , ... Today Aether announced that Aether and University of South Australia ... Melinda Gates Foundation grant, to pursue a 3D bioprinting research breakthrough ... the Gates Foundation, is said to be the largest transparently operated private foundation in ...
(Date:8/18/2017)... ... August 18, 2017 , ... OAI, a leading Silicon ... Microfluidics Industries, announces the new Model 800E front and backside, semi-automatic mask aligner ... mask aligners. OAI has already received and installed several orders for the ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... cancer research and personalized medicine, today announced the launch of a new breast ... Missouri. The study’s goal is to evaluate the potential for early detection of ...
(Date:8/16/2017)... Phoenix, Arizona (PRWEB) , ... ... ... is proud to introduce the Fluidnatek® Electrospinning and Electrospraying ... and electrospraying equipment scales from table-top equipment for the lab to fully ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):